Soft Tissue Sarcoma Market Analysis, Size, Share by 2023

Written by

Soft tissue sarcoma is associated with various rare cancers, which includes clear cell sarcoma, angiosarcoma, alveolar soft-part sarcoma, malignant mesenchymoma, adult fibrosarcoma, clear cell sarcoma, rhabdomyosarcoma, and kaposi sarcoma. Presently, there are limited treatment options available for soft tissue sarcoma. However, the RD pipelines are expected to grow in the forthcoming years.

In addition, increased focus on pacing up approval process is likely to expand overall care and treatment quality for soft tissue sarcoma in the years to come. Sunitinib (sutent), doxorubicin (adriamycin), trabectedin (yondelis), bevacizumab (avastin), and sirolimus (rapamune) are some of the pertinent drugs that are currently available. Nevertheless, adverse side-effects of the treatment, high cost and approval delays are some of the major market impediments.

Tremains the major driver of the global soft tissue sarcoma market. Market Research Future (MRFR) reports that the global soft tissue sarcoma market is set to grow at 8.2% CAGR during the assessment period (2017-2023).

Global Soft Tissue Sarcoma Market: Segmental Overview

The segmental analysis of the market has been conducted on the basis of disease type, treatment, end-users and distribution channel. Based on disease type, the market has been segmented into regional sarcoma, metastatic sarcoma, and local sarcoma. On the basis of treatment type, the market has been segmented into radiation therapy, anti-angiogenesis drugs, targeted therapy, and chemotherapy. The radiation therapy segment is further sub-segmented into external radiation therapy and internal radiation therapy.

Based on end user, the market has been segmented into long-term care centers, oncology centers and hospital. Based on distribution channel, the market has been segmented into retail pharmacies, hospital pharmacies and others.

Global Soft Tissue Sarcoma Market: Regional Segmentation

The regions covered in the report include the Middle East Africa (MEA), Asia Pacific (APAC), Europe and the Americas. In terms of revenue, the global soft tissue sarcoma market is dominated by the Americas with North America being the brighter market.

This is mainly owing to the presence of an advanced healthcare system in the region. Moreover, the rise in prevalence rate has also allowed the market to climb faster in the region. The data released by American Cancer Society, in 2016, approximately 12,390 people were suffering from soft tissue sarcoma or related cancer.

The market is also witnessing a steady growth in Europe. Higher rate of incidence and favourable reimbursement policies are some of factors that can be linked with the market growth in the region.

Asia Pacific (APAC) accounts for the third spot in the global soft tissue sarcoma market in terms of revenue. It is projected that the APAC soft tissue sarcoma market will witness a strong growth over the next couple of years. Healthcare policy reforms and increased efforts to improve healthcare services in countries such as China, India, Taiwan among others.

The Middle East Africa (MEA) market is also expected to exhibit a healthy growth over the next couple of years. In MEA, much of the growth will be driven by the strong investment in healthcare sector in GCC countries.

Global Soft Tissue Sarcoma Market: Competitive Landscape

GlaxoSmithKline plc (U.K), Pfizer, Inc. (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), Johnson Johnson Services, Inc. (U.S.), Bristol-Myers Squibb (U.S.), and Teva Pharmaceutical Industries Ltd (Israel) are among key company discussed in the MRFR’s report.

Industry News

  • Reportedly, the American pharmaceutical giant Eli Lilly has purchased the global rights for “CNTX-0290” the non-opioid pain candidate from Centrexion Therapeutics. The deal could garner close to $1 billion, plus royalties for the Boston-based company. CNTX-0290 is development phase and will be used for chronic pain associated with neuropathic, inflammatory and mixed pain conditions.
  • Epizyme, Inc, a late-stage biopharmaceutical firm focusing on new epigenetics therapies has recently released new data on on tazemetostat from the epithelioid sarcoma cohort of its active Phase 2 research in patients with molecularly defined solid tumours.


Article Categories:

Leave a Reply

Your email address will not be published. Required fields are marked *